Publications by authors named "E Fourmaux"

Claim this Profile
A
A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models.
Kamel Chettab, Chantel Fitzsimmons, Alexey Novikov, Morgane Denis, Capucine Phelip, Eric Fourmaux

Front Immunol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lux study: Contribution of a three-dimensional, high dynamic range, ultra-high-definition heads-up visualization system to a significant delivered light intensity decrease during different types of ocular surgeries.
L Vélasque, N Arbousoff, F Rigaudier, M Dominguez, E Fourmaux

J Fr Ophtalmol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema.
Laurent Kodjikian, Amélie Lecleire-Collet, Corinne Dot, Marie-Laure Le Lez, Stéphanie Baillif, Eric Fourmaux

Clin Ophthalmol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema.
Thi Ha Chau Tran, Ali Erginay, Stephane Verdun, Eric Fourmaux, Jean-François Le Rouic

Clin Ophthalmol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform.
Louise Conilh, Guy Fournet, Eric Fourmaux, Angélique Murcia, Eva-Laure Matera

Pharmaceuticals (Basel)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis